Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPENDD: Sensory Phenotyping to Enhance Neuropathic Pain Drug Development
NCT06614322Phase 2Recruiting
- Sponsor
- University of Rochester
- Start
- Feb 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peripheral neuropathy comparing Pregabalin, Duloxetine and Placebo (3 arms). Primary endpoint: Pain Intensity at 4 weeks. Started Feb 2026; status: recruiting.
02
Drugs
pregabalinduloxetine
03
Conditions
peripheral neuropathy
Beyond the preview
Go deeper on NCT06614322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614322.